Sorry, you need to enable JavaScript to visit this website.

We actively support our current portfolio companies throughout their growth cycles contributing strategic guidance in addition to capital as well as access to Pfizer expertise, when appropriate. 

Read our 2021 Year in Review Report
    • With a $600M capital commitment for investment, Pfizer Ventures backs private companies at all stages of development.
    • We have a strong focus on early-stage opportunities. But other investments, including start-ups and spinouts, are also considered in scope.
    • While primarily U.S. focused, international investments may represent up to 20 percent of the portfolio.
    • We can lead or join a syndicate of investors and will seek board representation commensurate with our investment.
    • Our investments are focused on potentially transformative therapeutics, with an emphasis in our core therapeutic areas: Inflammation & Immunology, Internal Medicine, Oncology, Rare Disease, and Vaccines.
    • We also consider platform technologies, diagnostics, drug delivery, pharmaceutical services, and other technologies that have the potential to transform drug discovery and development
    • Pfizer Ventures is an active investor, working with management to develop product strategy and shareholder value.
    • We bring a pharmaceutical perspective and have the potential to utilize our internal networks and expertise.
    • We have a streamlined approval process for investment decisions.
    • All investments have the potential for a business relationship with Pfizer.
    • Emphasis primarily on therapeutics (80%)
    • Platforms, tools, and technologies with potential to transform drug discovery and development are also considered (20%)
    • U.S. focused primarily
    • Approximately 20 percent of investments may be outside the U.S
    • Direct investing in private companies
    • All stages possible, with focus on early stage
    • Strategic and financial
    • Measured over long term
    • $600M current capital commitment from Pfizer AUM $1.3B
    • Up to $15M in first investment; reserved allocation for follow-on investments
    • Investing as member of a syndicate
    • Syndicate member must be located near company
    • Potential for business relationship with Pfizer considered in investment criteria
    • Can be transacted in parallel with investment or explored in the future
    • Contribute capital and industry experience to help guide development and company growth
    • Scientific advisory board participation when appropriate
    • Minority ownership positions
    • Board seats where appropriate
    • Traditional VC investment
    • Product rights not required

View a list of current and former companies that we've partnered with.

View Portfolio

Media Name: Barbara_v2_300x170.jpg

Vice President, WWBD / Senior Managing Partner

Media Name: Rana 300x170.jpg

Executive Director, WWBD / Partner

Media Name: KR_300x170.jpg

Executive Director, WRDM / Partner

irena_melnickova_300x170.jpg

Executive Director, WWBD and Partner at Pfizer Ventures

Media Name: Chris 300x170.png

Executive Director, WRDM / Partner

Media Name: Denis300x170.png

Vice President, WRDM / Managing Partner

marie-clarie_300x170.jpg

Executive Director, WRDM and Principal

Media Name: Barbara_v2_300x170.jpg

Vice President, WWBD / Senior Managing Partner

Media Name: Rana 300x170.jpg

Executive Director, WWBD / Partner

Media Name: KR_300x170.jpg

Executive Director, WRDM / Partner

irena_melnickova_300x170.jpg

Executive Director, WWBD and Partner at Pfizer Ventures

Media Name: Chris 300x170.png

Executive Director, WRDM / Partner

Media Name: Denis300x170.png

Vice President, WRDM / Managing Partner

marie-clarie_300x170.jpg

Executive Director, WRDM and Principal

Media Name: Barbara_v2_300x170.jpg

Vice President, WWBD / Senior Managing Partner

Media Name: Rana 300x170.jpg

Executive Director, WWBD / Partner

Media Name: KR_300x170.jpg

Executive Director, WRDM / Partner

irena_melnickova_300x170.jpg

Executive Director, WWBD and Partner at Pfizer Ventures

Media Name: Chris 300x170.png

Executive Director, WRDM / Partner

Media Name: Denis300x170.png

Vice President, WRDM / Managing Partner

marie-clarie_300x170.jpg

Executive Director, WRDM and Principal

Media Name: Barbara_v2_300x170.jpg

Vice President, WWBD / Senior Managing Partner

Media Name: Rana 300x170.jpg

Executive Director, WWBD / Partner

Media Name: KR_300x170.jpg

Executive Director, WRDM / Partner

irena_melnickova_300x170.jpg

Executive Director, WWBD and Partner at Pfizer Ventures

Media Name: Chris 300x170.png

Executive Director, WRDM / Partner

Media Name: Denis300x170.png

Vice President, WRDM / Managing Partner

marie-clarie_300x170.jpg

Executive Director, WRDM and Principal

Have an idea? Send us your opportunity for consideration.

Submit Your Opportunity